Literature DB >> 22349721

Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population.

Qitian Mu1, Qiuling Ma, Yungui Wang, Zhimei Chen, Xiangmin Tong, Fei-Fei Chen, Ying Lu, Jie Jin.   

Abstract

Cytogenetic analyses of chronic myelogenous leukemia (CML) have been performed previously in a large number of reports, but systematical research based on large sample sizes from the Chinese population is seldom available. In this study, we analyzed the cytogenetic profiles of 1,863 Philadelphia (Ph)/BCR-ABL-positive CML patients from a research center in China. Of 1,266 newly diagnosed CML patients, the median age was 41 years, which is younger than the median age of diagnosis in western populations. The incidence of additional chromosome abnormalities (ACA) was 3.1% in newly diagnosed chronic phase (CP), 9.1% in CP after therapy, 35.4% in accelerated phase, and 52.9% in blast crisis (BC), reflecting cytogenetic evolution with CML progression. A higher prevalence of ACA was observed in variant Ph translocations than in standard t(9;22) in the disease progression, especially in BC (88.2% vs. 50%, P = 0.002). Moreover, a hyperdiploid karyotype and trisomy 8 were closely correlated with myeloid BC, while a hypodiploid karyotype and monosomy 7 were associated with lymphoid-BC. Among subsets of myeloid-BC, myeloid-BC with minimal differentiation had a higher ACA rate than myeloid-BC with granulocytic differentiation (80% vs. 46.8%, P = 0.009) and myeloid-BC with monocytic differentiation (80% vs. 42.9%, P = 0.006). These data provide novel insights into cytogenetics of CML within the Chinese population.

Entities:  

Mesh:

Year:  2012        PMID: 22349721     DOI: 10.1007/s00277-012-1421-6

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  7 in total

1.  Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.

Authors:  W Wang; J E Cortes; P Lin; J D Khoury; D Ai; Z Tang; G Tang; J L Jorgensen; L J Medeiros; S Hu
Journal:  Leukemia       Date:  2015-04-14       Impact factor: 11.528

2.  Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.

Authors:  Wei Wang; Jorge E Cortes; Guilin Tang; Joseph D Khoury; Sa Wang; Carlos E Bueso-Ramos; Joseph A DiGiuseppe; Zi Chen; Hagop M Kantarjian; L Jeffrey Medeiros; Shimin Hu
Journal:  Blood       Date:  2016-03-22       Impact factor: 22.113

Review 3.  Chronic Myeloid Leukemia: Beyond BCR-ABL1.

Authors:  Ting Zhou; L Jeffrey Medeiros; Shimin Hu
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

4.  Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis.

Authors:  Wei Wang; Guilin Tang; Jorge E Cortes; Hui Liu; Di Ai; C Cameron Yin; Shaoying Li; Joseph D Khoury; Carlos Bueso-Ramos; L Jeffrey Medeiros; Shimin Hu
Journal:  J Hematol Oncol       Date:  2015-04-08       Impact factor: 17.388

5.  Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia.

Authors:  W Wang; Z Chen; Z Hu; C C Yin; S Li; S Bai; C E Bueso-Ramos; L J Medeiros; S Hu
Journal:  Blood Cancer J       Date:  2016-11-04       Impact factor: 11.037

6.  Down regulation of G protein-coupled receptor 137 expression inhibits proliferation and promotes apoptosis in leukemia cells.

Authors:  Li-Jie Men; Ji-Zhu Liu; Hai-Ying Chen; Li Zhang; Shuang-Feng Chen; Tai-Wu Xiao; Jing-Xia Wang; Guang-Yao Li; Ya-Ping Wu
Journal:  Cancer Cell Int       Date:  2018-01-29       Impact factor: 5.722

7.  Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China.

Authors:  Vikalp Kumar Maheshwari; Cassandra Slader; Nidhi Dani; Christina Gkitzia; Quan Yuan; Tengbin Xiong; Yu Liu; Ricardo Viana
Journal:  PLoS One       Date:  2021-10-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.